Serina Therapeutics (SER) AI Stock Analysis

• Market Cap: $26.02M
• Dividend Yield: N/A
• Average Volume (3M): 24.47K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.36
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 10,664,064
• 10 Day Avg. Volume: 14,098
• 30 Day Avg. Volume: 24,472
• PEG Ratio: <0.01
• Price to Book (P/B): 57.52
• Price to Sales (P/S): 658.37
• P/FCF Ratio: -2.15
• Enterprise Value/Market Cap: 2.10
• Enterprise Value/Revenue: 472.16
• Enterprise Value/Gross Profit: 829.85
• Enterprise Value/Ebitda: -2.96
• 1Y Price Target: $11.00
• Price Target Upside: 350.82% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $3.00 ▲(22.95% Upside)

Serina Therapeutics faces significant financial and operational challenges, reflected in its poor financial performance and technical indicators. The stock's valuation is also unattractive due to negative earnings. While recent financing for clinical trials is a positive development, it does not outweigh the substantial risks and inefficiencies currently present.

Positive Factors

Strategic Financing

The $20M financing for the Parkinson’s trial enhances Serina's ability to advance its clinical pipeline, supporting long-term growth and development.

Leadership Stability

The election of experienced directors provides governance stability, potentially improving strategic decisions and long-term company direction.

Regulatory Progress

Regulatory approvals for the Parkinson’s trial indicate progress in clinical development, enhancing the potential for future product commercialization.

Negative Factors

Financial Instability

High liabilities and negative equity indicate financial instability, which could hinder long-term operational flexibility and growth opportunities.

Cash Flow Challenges

Negative cash flow from operations suggests difficulty in sustaining core activities, potentially impacting long-term viability and strategic initiatives.

Declining Revenue

Declining revenue and negative margins highlight inefficiencies, threatening the company's ability to generate sustainable income and invest in growth.

Serina Therapeutics Business Overview & Revenue Model

Company Description

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

How the Company Makes Money

Serina Therapeutics generates revenue primarily through the commercialization of its proprietary drug delivery technologies and therapeutic products. The company may also engage in strategic partnerships and collaborations with larger pharmaceutical firms, which can provide upfront payments, milestone payments, and royalties on future sales. Additionally, research grants and funding from government agencies or private investors focused on innovative medical treatments contribute to its financial resources. The success of clinical trials and the approval of its products can significantly impact its revenue streams, as successful therapies move into the market.

Serina Therapeutics Financial Statement Overview

Summary

Serina Therapeutics is facing severe financial challenges across all key financial statements. The income statement reflects substantial losses and declining revenue, the balance sheet is under strain due to high liabilities and negative equity, and cash flow issues point to operational inefficiencies. These factors collectively suggest a need for strategic restructuring or significant operational improvements to ensure future viability.

Income Statement

Serina Therapeutics has experienced significant volatility in revenue and profitability. The TTM data shows a drastic decline in revenue, leading to negative gross and net profit margins. This indicates severe inefficiencies and a struggle to generate sufficient income. Previous periods also reflect a trend of high losses, with EBIT and EBITDA margins persistently underperforming.

Balance Sheet

The balance sheet shows a concerning financial structure with a very low equity base and high liabilities, resulting in a negative equity in some periods. The debt-to-equity ratio is not ideal, and the return on equity is not calculable due to negative equity. This suggests high financial risk and instability.

Cash Flow

The cash flow statement highlights consistent negative free cash flow, indicating operational challenges. The operating cash flow is significantly negative, suggesting that the company struggles to generate cash from its core activities. Despite some positive financing activities, the overall cash flow position is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	116.00K	56.00K	3.15M	500.00K	3.04M	54.00K
Gross Profit	66.00K	-138.00K	3.06M	500.00K	3.04M	-1.23M
EBITDA	-18.49M	-10.49M	5.92M	-2.60M	-1.23M	-8.74M
Net Income	-18.59M	-11.14M	5.27M	-2.68M	-1.26M	-10.87M
Balance Sheet
Total Assets	12.41M	6.72M	8.97M	3.24M	3.15M	3.92M
Cash, Cash Equivalents and Short-Term Investments	8.62M	3.67M	7.62M	645.00K	584.00K	527.00K
Total Debt	3.20M	268.00K	3.44M	18.12M	13.20M	6.30M
Total Liabilities	10.82M	6.22M	41.26M	20.56M	15.03M	9.32M
Stockholders Equity	1.76M	641.00K	-32.29M	-17.21M	-11.83M	-5.12M
Cash Flow
Free Cash Flow	-16.53M	-17.16M	-2.98M	-2.09M	-2.36M	-7.84M
Operating Cash Flow	-16.51M	-17.14M	-2.48M	-2.08M	-2.25M	-7.82M
Investing Cash Flow	-64.00K	-22.00K	-504.00K	980.94K	823.32K	-20.00K
Financing Cash Flow	21.96M	13.21M	10.07M	1.31M	1.08M	5.96M

Serina Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Negative. The current price of 2.44 is below the 20-day moving average (MA) of 3.20, below the 50-day MA of 3.94, and below the 200-day MA of 5.04, indicating a bearish trend. The MACD of -0.41 indicates Positive momentum. The RSI at 23.49 is Positive, neither overbought nor oversold. The STOCH value of 11.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SER.

Serina Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BRNS	41 Neutral	$28.64M	-0.37	-62.30%	―	-100.00%	-26.30%
SKYE	38 Underperform	$26.75M	-0.65	-94.31%	―	―	-53.18%
SER	38 Underperform	$26.02M	-0.41	―	―	―	―
CELU	38 Underperform	$37.59M	-0.40	―	―	-15.81%	-113.06%
OTLK	38 Underperform	$81.29M	―	―	―	―	86.28%

Serina Therapeutics Corporate Events

Serina Therapeutics Holds 2025 Annual Stockholders Meeting

On November 7, 2025, Serina Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders. During the meeting, Steve Ledger and Karen J. Wilson were elected as directors to serve until the 2028 Annual Meeting. Additionally, the appointment of Frazier & Deeter, LLC as the company’s independent auditors for the 2025 fiscal year was ratified. The issuance of common stock related to the Convertible Note and Warrants was also approved.

Serina Therapeutics Secures $5M for Parkinson’s Trial

On October 6, 2025, Serina Therapeutics announced the receipt of the first $5 million funding tranche from a $20 million financing agreement to support the registrational trial of SER-252 for advanced Parkinson’s disease. The company has submitted an IND to the FDA and received HREC approval in Australia, with the trial set to begin in Q4 2025, marking a significant step in addressing unmet needs for Parkinson’s patients.

Serina Therapeutics Secures $20M Convertible Note Agreement

On September 9, 2025, Serina Therapeutics entered into a $20 million unsecured convertible note agreement with board member Gregory H. Bailey, M.D. The funding, structured in five tranches, is tied to clinical and operational milestones, supporting the company’s SER-252-1b clinical study. This financial arrangement strengthens Serina’s operational capabilities and positions it strategically within the biotechnology sector. The agreement includes provisions for interest, conversion into common stock, and issuance of warrants, reflecting a significant step in the company’s growth and development plans.

Serina Therapeutics Secures $20M for Parkinson’s Trial

On September 9, 2025, Serina Therapeutics announced securing up to $20 million in financing to advance the registrational trial of SER-252 for Parkinson’s disease. This funding, led by Board Director Greg Bailey, MD, will support the Phase 1b clinical study under the 505(b)(2) NDA pathway. The financing structure allows flexibility in capital deployment and includes potential additional proceeds through warrant issuance. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of SER-252, a novel apomorphine therapy designed for continuous dopaminergic stimulation in advanced Parkinson’s patients. The study will be conducted in the U.S. and Australia, with key milestones anticipated in 2025 and 2026.